Advertisement

Topics

NicOx SA Company Profile

03:51 EST 19th November 2017 | BioPortfolio

NicOx aims to achieve profitability and growth through the research and development of nitric oxide therapeutics. NicOx begins its development process by taking well-known drugs and enhancing them with nitric oxide-releasing structures resulting in patentable new chemical entities.

Location

1900 Route des CrêtesBP 313
Sophia-Antipolis
F-06906
France

Contact

Phone: +33 (0)4 92387020
Fax: +33 (0)4 92387030


News Articles [49 Associated News Articles listed on BioPortfolio]

Nicox enters agreement with Eyevance for US commercialization of Zerviate

Nicox has signed an exclusive licensing agreement with Eyevance Pharmaceuticals for the commercialization of Zerviate in the United States, according to a Nicox press release.Eyevance will make a one-...

Nicox, Re-Vana enter collaboration agreement

Nicox and Re-Vana Therapeutics have entered a research collaboration to study the possibility of combining Nicox’s stand-alone nitric oxide donors with Re-Vana’s EyeLief drug delivery platform for...

Nicox : Rapport semestriel financier au 30 juin 2017

NICOX — Wednesday, September 13th 2017 at 8:55am UTC Communiqué de presse Nicox : Rapport semestriel financier au 30 juin 2017   13 septembre 2017 Sophia Antipolis, France   Le Rapport Semes...

NicOx partners on novel S-R ophthalmic formulation

French biotech firm NicOx has entered into a research collaboration with Northern Ireland-based Re-Vana…

Deals this week: NicOx, FibroGen, Omeros

NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in total.

NICOX :Assemblée Générale Ordinaire le 4 septembre 2017

NICOX — Friday, August 25th 2017 at 5:30am UTC Communiqué de presse Assemblée Générale Ordinaire le 4 septembre 2017   25 août 2017 – diffusion à 7h30 Sophia Antipolis, France   Ni...

NICOX : Déclaration des droits de vote au 30 juin 2017

NICOX — Monday, July 3rd 2017 at 3:45pm UTC Nicox SA Société anonyme au capital de 25 669 338 euros Siège social :DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRA...

NICOX : Nombre de droits de vote au 17 juillet 2017

NICOX — Tuesday, July 18th 2017 at 3:40pm UTC Nicox SA Société anonyme au capital de 25 669 338 euros Siège social :DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. G...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

NicOx SA

NicOx aims to achieve profitability and growth through the research and development of nitric oxide therapeutics. NicOx begins its development process by taking well-known drugs and enhancing them wit...

NicOx S.A

NicOx is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs.NicOx is targeting the therapeutic areas of inflammation and...

NicOx

More Information about "NicOx SA" on BioPortfolio

We have published hundreds of NicOx SA news stories on BioPortfolio along with dozens of NicOx SA Clinical Trials and PubMed Articles about NicOx SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NicOx SA Companies in our database. You can also find out about relevant NicOx SA Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record